https://en.bioecon.ru/niches/diagnostics/Recent content in Diagnostics on BioeconHugoen-USMon, 20 Jul 2026 20:38:18 +0700https://en.bioecon.ru/technology/ai-optical-coherence-tomography-screening/Mon, 20 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/ai-optical-coherence-tomography-screening/AI-assisted optical coherence tomography and fundus imaging for broad-disease eye screening — diabetic retinopathy, age-related macular degeneration and glaucoma — spanning home-use monitoring devices, multimodal clinic platforms and autonomous AI diagnostic software: Notal Vision and iHealthScreen in the US, Topcon Healthcare (Japan), RetinAI in Switzerland (acquired by EssilorLuxottica), and Airdoc in China.https://en.bioecon.ru/technology/biobanks-human-population-samples/Mon, 20 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/biobanks-human-population-samples/Physical infrastructure for collecting, processing, cryopreserving and distributing human biospecimens at population or clinical-trial scale — the biospecimen logistics layer, not the genomic-data repository itself: UK Biobank in the EU, BioLife Solutions and Discovery Life Sciences in the US, the China National GeneBank in China, and the newly inaugurated Phenome-India National Biobank (CSIR-IGIB) in India.https://en.bioecon.ru/technology/companion-diagnostics-platforms/Mon, 20 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/companion-diagnostics-platforms/Tissue-based immunohistochemistry (IHC) and FISH platforms that determine whether a specific patient is eligible for a specific targeted therapy, sold and regulated as a companion diagnostic (CDx) tied directly to a drug label — distinct from blood-based liquid-biopsy CDx: Ventana/Roche Tissue Diagnostics, Agilent Dako and Myriad Genetics in the US, 3D Medicines in China, and MedGenome in India.https://en.bioecon.ru/technology/exhaled-breath-glucose-monitoring/Mon, 20 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/exhaled-breath-glucose-monitoring/Non-invasive breath-analyte devices aiming to monitor diabetes-relevant metabolic state without a fingerstick or implanted sensor — most commercially advanced platforms detect breath acetone/ketones as a metabolic proxy, while newer entrants target a more direct blood-glucose alert claim: PranaQ, Invoy Technologies, LEVL and PREEVNT, all US-based.https://en.bioecon.ru/technology/genomic-pathogen-surveillance/Mon, 20 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/genomic-pathogen-surveillance/Sequencing-based services that track pathogen genomic evolution and spread for public health response — traveler/airport biosurveillance, portable field sequencing and national metagenomic surveillance programs — the genomic-analysis service layer, not the sample-collection infrastructure: Ginkgo Bioworks (Concentric) in the US, Oxford Nanopore Technologies and the Wellcome Sanger Institute/UKHSA in the UK, BGI Genomics in China, and the Rajiv Gandhi Centre for Biotechnology in India.https://en.bioecon.ru/technology/home-blood-analysis-kits/Mon, 20 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/home-blood-analysis-kits/Self-administered blood collection for consumer health testing, either mailed to a certified laboratory or drawn at a retail microsample station, returning results outside a clinic visit — distinct from clinic point-of-care testing: LetsGetChecked and Everlywell (mail-in kits) and Babson Diagnostics (retail microsample testing) in the US, and Thriva in the UK.https://en.bioecon.ru/technology/implantable-biosensors-chronic-disease/Mon, 20 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/implantable-biosensors-chronic-disease/Surgically or subcutaneously implanted sensors that continuously monitor a chronic-disease parameter for months to years without an external wearable — implantable continuous glucose monitors and insertable cardiac monitors — distinct from external wearables and ingested/swallowed sensors: Senseonics’ Eversense 365 in the US, Medtronic’s LINQ II and Boston Scientific’s LUX-Dx cardiac monitors in the US, Biotronik’s BIOMONITOR in Germany, and MicroPort in China.https://en.bioecon.ru/technology/ingestible-biosensors-smart-pills/Mon, 20 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/ingestible-biosensors-smart-pills/Swallowed capsule devices that image the GI tract or confirm medication ingestion as they transit the body, requiring no sedation or implantation — distinct from surgically implanted sensors: Medtronic’s PillCam and CapsoVision’s CapsoCam capsule endoscopy in the US, etectRx’s ID-Cap ingestible event marker in the US, and Ankon Technologies’ magnetically controlled capsule endoscopy in China.https://en.bioecon.ru/technology/intraoperative-molecular-diagnostics/Mon, 20 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/intraoperative-molecular-diagnostics/Real-time, in-the-operating-room molecular and optical tissue identification — fluorescence imaging agents, OCT, stimulated Raman histology and mass-spectrometry tissue analysis — that lets surgeons assess tumor margins during the procedure instead of waiting on frozen-section pathology: On Target Laboratories and Dilon Technologies (fluorescence/RF-spectroscopy margin agents), Perimeter Medical Imaging AI (AI-enabled OCT), Invenio Imaging (stimulated Raman histology) in the US, and photonamic and Imperial College London (iKnife/REIMS) in Europe.https://en.bioecon.ru/technology/liquid-biopsy-ctdna-diagnostics/Mon, 20 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/liquid-biopsy-ctdna-diagnostics/Blood-based detection and quantification of circulating tumor DNA (ctDNA) for cancer companion diagnostics and molecular residual disease (MRD) monitoring, replacing or supplementing tissue biopsy — led by Guardant Health, Natera and Foundation Medicine in the US, Sysmex Inostics in the EU, MedGenome in India, and Burning Rock Biotech in China.https://en.bioecon.ru/technology/microbiome-diagnostic-panels/Mon, 20 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/microbiome-diagnostic-panels/Stool- or swab-based sequencing panels that profile the gut or GI microbiome for consumer wellness insight or clinical pathogen/dysbiosis detection, distinct from general human genomics services: Viome (US, consumer wellness) and Codex Genetics (US, clinical metagenomics), Sequentia Biotech’s IVDR-CE-marked MICK Clinical in Spain, Realbio Genomics in China, and Yaazh Xenomics in India.https://en.bioecon.ru/technology/multi-cancer-early-detection/Mon, 20 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/multi-cancer-early-detection/A single blood draw screening asymptomatic, average-risk individuals for signals of dozens of cancer types simultaneously, aiming to catch cancer before symptoms appear — distinct from treatment-matched companion diagnostics: GRAIL’s Galleri (US), Exact Sciences’ Cancerguard (US) and Freenome (US), Novigenix in Switzerland, and Singlera Genomics in China.https://en.bioecon.ru/technology/multi-omics-diagnostic-panels-precision-oncology/Mon, 20 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/multi-omics-diagnostic-panels-precision-oncology/Integrative genomic, transcriptomic and proteomic oncology profiling platforms that combine multiple molecular data layers into a single treatment-matching report, broader than a single drug-label companion diagnostic: Tempus AI and Caris Life Sciences in the US, Sophia Genetics in Switzerland, Geneseeq Technology in China, and 1cell.ai in India.https://en.bioecon.ru/technology/point-of-care-molecular-diagnostics/Mon, 20 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/point-of-care-molecular-diagnostics/Lab-free, sample-to-answer molecular testing platforms delivering PCR-grade results at the bedside, clinic or field site in minutes rather than the hours a central lab requires: Cepheid’s GeneXpert (Danaher) and bioMérieux’s BIOFIRE cartridge-based systems, Abbott’s ID NOW isothermal platform, Sansure Biotech’s domestic POCT scale-up in China, and Molbio Diagnostics’ Truenat chip-based platform serving resource-limited settings from India.https://en.bioecon.ru/technology/rapid-antibiotic-resistance-tests/Mon, 20 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/rapid-antibiotic-resistance-tests/Platforms that determine which antibiotics a specific infecting pathogen is susceptible or resistant to in hours instead of the 2-3 days conventional culture-based susceptibility testing requires, guiding targeted rather than empiric antibiotic therapy: Accelerate Diagnostics and T2 Biosystems and Selux Diagnostics in the US, Q-linea in Sweden, and Autobio Diagnostics in China.https://en.bioecon.ru/technology/retinal-biomarkers-neurodegenerative-disease/Mon, 20 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/retinal-biomarkers-neurodegenerative-disease/Eye-scan technologies that detect Alzheimer’s and other neurodegenerative-disease biomarkers directly in the retina — a window onto brain pathology accessible without imaging the brain itself — spanning hyperspectral imaging, OCT-based structural biomarkers and retinal amyloid detection: RetiSpec and NeuroVision Imaging in North America, Optina Diagnostics in Canada, and Heidelberg Engineering in Germany.https://en.bioecon.ru/technology/synthetic-biomarkers/Mon, 20 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/synthetic-biomarkers/Engineered, exogenous reporter molecules — activity-based nanosensors, synthetic gene circuits and volatile-organic-compound probes — administered to a patient to generate an amplified, easily measured disease signal that no endogenous biomarker naturally produces: Glympse Bio, Earli and ZymoSense in the US, and Owlstone Medical’s EVOC breath-probe platform in the UK.https://en.bioecon.ru/technology/tear-fluid-biopsy/Mon, 20 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/tear-fluid-biopsy/Point-of-care diagnostic testing of a microliter tear sample for dry eye, ocular allergy and inflammatory biomarkers, avoiding blood draw or invasive sampling: Trukera Medical’s tear osmolarity system and Lacrisciences’ tear IgE allergy test and QuidelOrtho’s InflammaDry inflammatory marker test in the US, and DiagnosTear’s TearX platform in France.https://en.bioecon.ru/technology/metabolomics-service/Sat, 04 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/metabolomics-service/Contract research platforms that profile the small-molecule metabolome of blood, tissue or bioreactor broth via LC-MS/GC-MS, turning raw chromatography data into biomarker panels, drug-response readouts and bioprocess metabolic profiles for pharma, nutrition and industrial-fermentation clients.https://en.bioecon.ru/technology/veterinary-genomics-companion-animal-diagnostics/Fri, 03 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/veterinary-genomics-companion-animal-diagnostics/Direct-to-consumer DNA testing of dogs and cats — a stack from cheek-swab collection to a LIMS-verified veterinary genetic passport screening hundreds of inherited disease risks.https://en.bioecon.ru/technology/wastewater-based-epidemiology/Sun, 28 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/wastewater-based-epidemiology/Aggregate, non-invasive molecular surveillance of municipal sewage for pathogens, antimicrobial resistance and substance use — an early-warning public-health intelligence service built on viral concentration, droplet-digital PCR and metagenomic sequencing.https://en.bioecon.ru/technology/personalized-nutrition/Fri, 26 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/personalized-nutrition/Dietary recommendations tailored to an individual’s gut microbiome, DNA and real-time glucose response, delivered as test-kit subscriptions, AI food scores and custom-formulated supplements.https://en.bioecon.ru/technology/breathomics/Thu, 25 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/breathomics/Non-invasive breath analysis using VOC patterns for early diagnosis and continuous disease monitoring.https://en.bioecon.ru/technology/organoids-organ-on-chip/Thu, 25 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/organoids-organ-on-chip/Microphysiological systems mimicking human organs in vitro to replace animal testing and accelerate personalized medicine.https://en.bioecon.ru/technology/personalized-diagnostics/Thu, 25 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/personalized-diagnostics/Molecular diagnostics leveraging NGS, liquid biopsy, and AI for precision medicine and targeted therapies.https://en.bioecon.ru/technology/wearable-biodiagnostics/Thu, 25 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/wearable-biodiagnostics/Wearable biodiagnostics and continuous monitoring systems enabling real-time precision health management.https://en.bioecon.ru/technology/biosensors-continuous-monitoring/Wed, 24 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/biosensors-continuous-monitoring/Advanced inline and online bioprocess sensors utilizing optics, capacitance, and spectrometry for real-time monitoring of biomass, metabolites, and dissolved gases in industrial fermentation.https://en.bioecon.ru/technology/crispr-diagnostics/Sun, 14 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/crispr-diagnostics/Cas-enzyme nucleic-acid detection — point-of-care molecular diagnostics from sample to lateral-flow readout.